Pfizer wins FDA approval for 'first and only' oral treatment for prostate cancer drug
Pfizer Inc. confirmed that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application to treat prostate cancer.
The New York-based pharma giant, which opened Tuesday morning at $39.46 a share, created the new cancer drug with Japan-based Astellas Pharma Inc.
The treatment, Xtandi, helps patients with metastatic hormone-sensitive prostate cancer (mCSPC). This type of prostate cancer spreads to other parts o f the body.
In 2019, it is estimated that just over 40,000…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Anthony Noto Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health Management | Hormones | Japan Health | New Drug Applications | Oral Cancer | Pfizer | Pharmaceuticals | Prostate Cancer